{"allTrials": {"@totalCount": "4", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2009-09-29T00:00:00.000Z", "@version": "25", "isrctn": {"@dateAssigned": "2006-07-26T00:00:00.000Z", "#text": "57452882"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age", "scientificTitle": null, "acronym": null, "studyHypothesis": "Prevention of severe rotavirus diarrhoea in infants by vaccination with the oral rotavirus candidate vaccine 116E, naturally attenuated and reassorted in nature, isolated from an asymptomatic infant.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Evaluation of the safety of vero cell based 116E rotavirus vaccine candidate strain 116E administered three times orally at four week intervals.", "secondaryOutcome": "Evaluation of the immunogenicity of vero cell based 116E rotavirus vaccine candidate strain 116E administered three times orally at four week intervals.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approved by Independent Ethics Committee and Institutional Review Boards."}, "externalRefs": {"doi": "10.1186/ISRCTN57452882", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": "NCT00439660", "protocolSerialNumber": "Protocol No. 1"}, "trialDesign": {"studyDesign": "Randomised double blind placebo controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-08-16T00:00:00.000Z", "overallEndDate": "2008-02-15T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "India"}, "trialCentres": {"trialCentre": {"@id": "1393f5e7-2768-4902-9283-8bd3f90d6028", "name": "B-10", "address": null, "city": "New Delhi", "state": null, "country": "India", "zip": "110 017"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Access to a telephone\n2. Healthy male and female non-malnourished infants aged six weeks (till six weeks + two days)\n3. Parents' permission to participate\n4. No plans to travel over the next four months", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Weeks", "@value": "6.0"}, "upperAgeLimit": {"@unit": "Weeks", "@value": "6.0"}, "gender": "Both", "targetEnrolment": "540", "totalFinalEnrolment": null, "totalTarget": "540", "exclusion": "1. Gestational age less than 37 weeks\n2. Any major physical congenital malformation\n3. Contact with immunosuppressed individuals\n4. Hospitalised once or more for the following illnesses since birth: heart disease, pneumonia, sepsis, meningitis, unconsciousness\n5. Daily medications other than vitamins or herbal \"tonics\"\n6. Evidence of cardiovascular disease\n7. Evidence of gastrointestinal disease<br/8. Evidence of neurological disease\n9. Evidence of liver or reticuloendothelial disease\n10. Evidence of hematologic, rheumatologic or immunologic disease\n11. Evidence of renal disease", "patientInfoSheet": null, "recruitmentStart": "2006-08-16T00:00:00.000Z", "recruitmentEnd": "2008-02-15T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Severe rotavirus diarrhoea", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Viral and other specified intestinal infections"}}, "interventions": {"intervention": {"description": "Prevention of severe rotavirus diarrhea by vaccination with oral rotavirus candidate vaccine 116E, live attenuated. The control group will receive a placebo vaccine.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase I/II", "drugNames": "Rotavirus candidate vaccine 116E"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19545211 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "dea532ed-667d-4174-b942-c96af8a80eef", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19545211"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder15238-0", "contactId": "Contact53138_15238", "sponsorId": "Sponsor51679"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53138_15238", "title": "Dr", "forename": "Nita", "surname": "Bhandari", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "B-10\nSoami Nagar", "city": "New Delhi", "country": "India", "zip": "110 017", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+91 (0)11 2601 4136 / 6599"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "community.research@cih.uib.no"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51679", "organisation": "Bharat Biotech International Ltd (India)", "website": "http://www.bharatbiotech.com", "sponsorType": "Industry", "contactDetails": {"address": "Genome Valley\nShameerpet (M)", "city": "Hyderabad", "country": "India", "zip": "500 078", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+91 (0)40 2348 0567"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "info@bharatbiotech.com"}}, "privacy": "Public", "gridId": "grid.497429.5", "rorId": "https://ror.org/00rm8g048"}, "funder": {"@id": "Funder15238-0", "name": "Bill and Melinda Gates Foundation (BMGF) through Program for Appropriate Technology in Health (PATH) (USA)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-29T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2006-03-30T00:00:00.000Z", "#text": "28353453"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A controlled trial of terlipressin plus banding ligation versus terlipressin alone in the management of acute esophageal variceal bleeding", "scientificTitle": null, "acronym": null, "studyHypothesis": "The majority of patients with acute oesophageal variceal bleeding stop bleeding during endoscopy. It is still unknown whether endoscopic therapy is beneficial in those patients with acute inactive oesophageal variceal bleeding.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Initial control of variceal bleeding after 48 hours of treatment", "secondaryOutcome": "Early rebleeding between 48-120 hours after treatment", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approved by the Veterans General Hospital Kaohsiung (VGHKS), reference number: 94-CT1-01"}, "externalRefs": {"doi": "10.1186/ISRCTN28353453", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NSC 94-2314-B-075B-010"}, "trialDesign": {"studyDesign": "Randomised active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-01-01T00:00:00.000Z", "overallEndDate": "2007-07-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Taiwan"}, "trialCentres": {"trialCentre": {"@id": "520e1782-4523-43e0-998f-9c8bc8d8d627", "name": "386 Ta-Chung 1st Road", "address": null, "city": "Kaohsiung", "state": null, "country": "Taiwan", "zip": "813"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Cirrhotic patients\n2. Acute oesophageal variceal bleeding proven by emergency endoscopy within 12 hours", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "120", "totalFinalEnrolment": null, "totalTarget": "120", "exclusion": "1. Association with advanced hepatocellular carcinoma (HCC)\n2. Association with other severe systemic illness\n3. Association with gastric variceal bleeding\n4. Previous shunt operation, endoscopic variceal ligation (EVL), beta-blocker or isosorbide mononitrate (ISMN) within one month\n5. Serum bilirubin >10 mg/dl, creatinine >3 mg/dl\n6. Presence of encephalopathy >grade 2\n6. History of coronary artery disease\n7. Uncooperative", "patientInfoSheet": null, "recruitmentStart": "2005-01-01T00:00:00.000Z", "recruitmentEnd": "2007-07-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Acute oesophageal variceal bleeding but stopped bleeding during emergency endoscopy", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Oesophageal varices"}}, "interventions": {"intervention": {"description": "Group 1: terlipressin infusion for five days\nGroup 2: banding ligation performed during emergency endoscopy and terlipressin infusion for two days", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Terlipressin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19386609 results", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "144ee5d4-dd34-419c-8078-b6c55b4d7d2b", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-09-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19386609"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder14820-0", "contactId": "Contact52589_14820", "sponsorId": "Sponsor51113"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52589_14820", "title": "Prof", "forename": "Gin-Ho", "surname": "Lo", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "386 Ta-Chung 1st Road", "city": "Kaohsiung", "country": "Taiwan", "zip": "813", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+886 (0)7 3422121/2075"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ghlo@isca.vghks.gov.tw"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51113", "organisation": "Republic of China National Science Council (Taiwan)", "website": null, "sponsorType": "Government", "contactDetails": {"address": "106 Ho-Ping East Road\nSection 2", "city": "Taipei", "country": "Taiwan", "zip": "106", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+886 (0)2 27377541"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "pihsu@vghks.gov.tw"}}, "privacy": "Public", "gridId": "grid.410767.3", "rorId": "https://ror.org/02kv4zf79"}, "funder": {"@id": "Funder14820-0", "name": "Republic of China National Science Council (Taiwan)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-29T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2005-08-23T00:00:00.000Z", "#text": "30183796"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Process and outcome of day clinic and inpatient psychotherapy in severe bulimia nervosa: a randomised-controlled trial", "scientificTitle": null, "acronym": null, "studyHypothesis": "1. 3 month follow-up:\n1.1. Inpatients will suffer from more relapses after discharge (bulimic\nsymptoms)\n1.2. Inpatients will show less feelings of specific self-efficiacy compared\nwith day clinic patients between discharge and 3-month-follow-up\n1.3. Day clinic patients will show some improvement in social adjustment whereas after inpatient treatment there will be no change\n\n2. 12 month follow up:\n2.1. Both groups will show comparable results in general and specific\npathology\n2.2. Day clinic patients will show more improvements in social adjustment\n2.3. Day clinic patients will be more satisfied with treatment in retrospect", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Eating- Disorder-Inventory (EDI-II) (scale 2: bulimia)\n2. Symptom-Check-List (SCL-90-R)\n3. Global Severity Index (GSI)\n4. Self-Efficiacy-Questionnaire; Social Adjustment Scale (SAS) (total score)", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN30183796", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "ZE 520/4-1"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-01-01T00:00:00.000Z", "overallEndDate": "2006-03-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "ce121fa6-8bb6-4745-9ea8-32e9df9669e7", "name": "Dept. of Psychosomatic Medicine and Psychotherapy", "address": null, "city": "Freiburg", "state": null, "country": "Germany", "zip": "79104"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Bulimia nervosa: International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD 10) / Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV)\n2. Age >17\n3. Indication for day clinic/inpatient treatment \n3.1. failure of outpatient psychotherapy\n3.2. chronicity\n3.3. severe symptom expression\n3.4. severe comorbidity", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "60", "totalFinalEnrolment": null, "totalTarget": "60", "exclusion": "1. Severe, acute somatic complications\n2. Psychosis\n3. Severe addiction (detoxification is needed)\n4. Acute suicidality\n5. Clinic can not be reached within a reasonable time (>60 minutes travel time)", "patientInfoSheet": null, "recruitmentStart": "2003-01-01T00:00:00.000Z", "recruitmentEnd": "2006-03-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Severe bulimia nervosa", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Eating disorders"}}, "interventions": {"intervention": {"description": "3 month of day clinic or inpatient treatment (multimodal treatment) with the same treatment elements in similar quantity in both conditions (individual and group therapy, work with eating diaries, rounds, art therapy, body therapy etc.). The treatment concept is psychodynamic, integrating cognitive-behavioral and family-oriented elements.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19270470 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "ee610eb9-a7d6-46a2-9dac-fa6154a131b1", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19270470"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder13124-0", "contactId": "Contact50666_13124", "sponsorId": "Sponsor49050"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50666_13124", "title": "Dr", "forename": "Almut", "surname": "Zeeck", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Dept. of Psychosomatic Medicine and Psychotherapy\nUniversity of Freiburg\nHauptstrasse 8", "city": "Freiburg", "country": "Germany", "zip": "79104", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)761 2706806"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "almut.zeeck@uniklinik-freiburg.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor49050", "organisation": "German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG) (Germany)", "website": "http://www.dfg.de/", "sponsorType": "Research organisation", "contactDetails": {"address": "Kennedyallee 40", "city": "Bonn", "country": "Germany", "zip": "53170", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)228 8852824"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "astrid.golla@dfg.de"}}, "privacy": "Public", "gridId": "grid.424150.6", "rorId": "https://ror.org/018mejw64"}, "funder": {"@id": "Funder13124-0", "name": "German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG) (Germany) - (ref: ZE 520/4-1_", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-09-29T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2000-10-03T00:00:00.000Z", "#text": "58987964"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open randomised trial to evaluate the activity and tolerability of combinations of reverse transcriptase and protease inhibitors, including induction therapy, in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection and CD4 cell counts greater than 25 x 10 to the power of 6 per litre", "scientificTitle": null, "acronym": "The FORTE trial", "studyHypothesis": "To evaluate, in patients starting anti-HIV therapy, the activity over at least 48 weeks of two regimens in terms of effects on plasma HIV RNA, CD4 cell counts, viral resistance, progression of HIV disease and survival, and safety and tolerability.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Virological failure defined as failure to achieve  plasma HIV RNA less than 50 copies per millilitre during the first 24 weeks or, having achieved such a level of suppression, subsequent rebound of plasma HIV RNA  above 400 copies per millilitre.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN58987964", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "G9719167 (extension, ProCom trial)"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1999-10-01T00:00:00.000Z", "overallEndDate": "2002-07-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "3f6d0e0c-2e59-4fa7-afaa-1fb6d497796f", "name": "MRC Clinical Trials Unit", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "NW1 2DA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Age 18 years or more with documented HIV-1 infection and requiring anti-retroviral therapy\n2. CD4 count greater than 25 x 10 to the power of 6 per litre\n3. Any stage of HIV disease including recent infection (except acute symptomatic primary infection)\n4. Likely to survive at least 2 years and take the allocated therapy for at least 6 months\n5. Able to give informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "100", "totalFinalEnrolment": null, "totalTarget": "100", "exclusion": "1. Previous anti-retroviral treatment or immunotherapies\n2. Peripheral nephropathy or a history of pancreatitis\n3. Women who are pregnant, breastfeeding or not taking adequate contraception\n4. Heterosexual men not willing to use barrier contraception \n5. Receiving combination chemotherapy for cancer\n6. Receiving parenteral therapy for an opportunistic infection\n7. Unlikely to comply with the protocol\n8.  At screening with creatinine above upper limit of normal (ULN), ALT or AST above 2.5 times ULN, amylase above 1.5 times ULN (except if pancreatic amylase less than 1.5 times ULN), haemoglobin less than 10.5g/dl, neutrophils less than 1.0 or platelets less than 100", "patientInfoSheet": null, "recruitmentStart": "1999-10-01T00:00:00.000Z", "recruitmentEnd": "2002-07-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "HIV, Acquired Immunodeficiency Syndrome (AIDS)", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Human Immunodeficiency Virus-1 (HIV-1)"}}, "interventions": {"intervention": {"description": "1. Didanosine (ddI), Stavudine (d4T), Nevirapine (NVP) plus Nelfinavir (NFV) for at least 24 weeks, then ddI, d4T and NVP as maintenance therapy\n2.  Continuous ddI, d4T plus NVP\n\nNote: third arm with continuous ddI, d4T, NVP plus NFV deleted November 2000.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "2 regimens"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17503747 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "ed80265c-2e65-42a2-9e1b-eb68b587eeb4", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-10-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17503747"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder1111-0", "contactId": "Contact55549_1111", "sponsorId": "Sponsor5055"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55549_1111", "title": "Dr", "forename": "Malcolm", "surname": "Hooker", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "MRC Clinical Trials Unit\n222 Euston Road", "city": "London", "country": "United Kingdom", "zip": "NW1 2DA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5055", "organisation": "Medical Research Council (MRC) (UK)", "website": "http://www.mrc.ac.uk", "sponsorType": "Research council", "contactDetails": {"address": "20 Park Crescent", "city": "London", "state": null, "country": "United Kingdom", "zip": "W1B 1AL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7636 5422"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "clinical.trial@headoffice.mrc.ac.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder1111-0", "name": "Medical Research Council (MRC) (UK)", "fundRef": "http://dx.doi.org/10.13039/501100000265"}}]}}